The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses

  • Authors:
    • Anita Schmitt
    • Thomas F.E. Barth
    • Eva Beyer
    • Franziska Borchert
    • Markus Rojewski
    • Jinfei Chen
    • Philippe Guillaume
    • Silke Gronau
    • Jochen Greiner
    • Peter Möller
    • Herbert Riechelmann
    • Michael Schmitt
  • Corresponding author:
  • View Affiliations

  • Published online on: Sunday, March 1, 2009
  • Pages: 629-639 DOI: 10.3892/ijo_00000188

Abstract

Despite advances in surgery, radio- and chemotherapy, therapeutic approaches for patients with head and neck squamous carcinoma (HNSCC) need to be improved. Immunotherapies eliciting tumor specific immune responses might constitute novel treatment options. We therefore investigated the expression and immunogenicity of two tumor-associated antigens (TAA) the receptor for hyaluronic acid mediated motility (RHAMM) and carboanhydrase IX (G250/CAIX) in HNSCC patients. Twenty-two HNSCC samples were examined for the expression of RHAMM and G250 by Western blotting and immunohistochemistry, 14/22 samples were tested for HLA-A2 expression by flow cytometry. For 8/22 samples single tumor-cell suspensions were generated, and mixed lymphocyte peptide cultures (MLPC) were performed to evaluate the frequencies of cytotoxic T cells specifically recognizing RHAMM and G250 using Tetramer staining/multi-color flow cytometry and enzyme linked immunosorbent spot (ELISPOT) assays. RHAMM and G250 were expressed in 73 and 80% of the HNSCC samples at the protein level. A co-expression of both TAAs could be detected in 60% of the patients. In 4/8 HLA-A2+ patients, 0.06-0.13% of CD8+ effector T cells recognized Tetramers for RHAMM or G250 and secreted IFNγ and granzyme B in ELISPOT assays. RHAMM and G250 are expressed at high frequency and high protein level in HNSCCs and are recognized by cytotoxic CD8+ effector T cells. Therefore both TAAs constitute interesting targets for T cell based immunotherapies for HNSCC.
Journal Cover

March 2009
Volume 34 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

2013 Impact Factor: 2.773
2014 I.F. (Expected) ≥ 3.310 Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Schmitt, A., Barth, T.F., Beyer, E., Borchert, F., Rojewski, M., Chen, J. ... Schmitt, M. (2009). The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses. International Journal of Oncology, 34, 629-639. http://dx.doi.org/10.3892/ijo_00000188
MLA
Schmitt, A., Barth, T. F., Beyer, E., Borchert, F., Rojewski, M., Chen, J., Guillaume, P., Gronau, S., Greiner, J., Möller, P., Riechelmann, H., Schmitt, M."The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses". International Journal of Oncology 34.3 (2009): 629-639.
Chicago
Schmitt, A., Barth, T. F., Beyer, E., Borchert, F., Rojewski, M., Chen, J., Guillaume, P., Gronau, S., Greiner, J., Möller, P., Riechelmann, H., Schmitt, M."The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses". International Journal of Oncology 34, no. 3 (2009): 629-639. http://dx.doi.org/10.3892/ijo_00000188